Additionally, the inhibitor SBI‐581 can significantly suppress cell autophagy mediated by TAOK3 and synergizes with cisplatin to treat ESCC in vitro and in vivo. This evidence concerns the gene TAOK3 and esophageal squamous cell carcinoma.